Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab

BACKGROUND: The safety of pembrolizumab monotherapy in treatment‐naïve non‐small cell lung cancer (NSCLC) patients with high programed death‐ligand 1 (PD‐L1) expression and pre‐existing interstitial lung disease (ILD) has not yet been determined. Here, we aimed to evaluate the prognosis, efficacy an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Thorac Cancer
Asıl Yazarlar: Yamaguchi, Ou, Kaira, Kyoichi, Shinomiya, Shun, Mouri, Atsuto, Hashimoto, Kosuke, Shiono, Ayako, Miura, Yu, Akagami, Tomoe, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons Australia, Ltd 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7862785/
https://ncbi.nlm.nih.gov/pubmed/33185333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13725
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller